Long-Acting Drug Delivery Technologies and Services Market - Distribution by Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Compatible Dosage Form (Injectables, Implantables, Oral, Topical / Transdermal, Vaginal and Other Dosage Forms), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    270

  • View Count
    407

Example Insights

Long-Acting-Drug-Delivery-Technologies-Context-thumb Long-Acting-Drug-Delivery-Technologies-List-thumb Long-Acting-Drug-Delivery-Technologies-Distribution-by-Strategy-thumb Long-Acting-Drug-Delivery-Technologies-Competitiveness-Analysis-thumb Long-Acting-Drug-Delivery-Technologies-Current-Service-Providers-thumb
Long-Acting-Drug-Delivery-Technologies-Dosage-Forms-thumb Long-Acting-Drug-Delivery-Technologies-Service-Portfolio-thumb Long-Acting-Drug-Delivery-Technologies-Partnerships-and-Collaboration-thumb Long-Acting-Drug-Delivery-Technologies-Publication-Analysis-thumb Long-Acting-Drug-Delivery-Technologies-Patent-Analysis-thumb
Long-Acting-Drug-Delivery-Technologies-Grant-Analysis-thumb Long-Acting-Drug-Delivery-Technologies-Likely-Growth-Scenarios-thumb Long-Acting-Drug-Delivery-Technologies-Geographical-Regions-thumb    

Overview

Long-acting drug delivery is an innovative drug delivery approach which allows sustained action of a drug for weeks, months or years after single administration and maintains its optimal therapeutic level in the patient’s body. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. It is worth mentioning that a suitable combination of dosage form (long-acting implants, injectables, vaginal, oral and topical / transdermal dosage forms) and strategy (micro-encapsulation, nanocrystal suspensions, long-acting hydrogels and microneedles) enables better biodistribution and exertion of a localized therapeutic action of the drug for an extended duration. Driven by the ongoing pace of innovation in the formulation of these technologies and the increasing demand for long-acting drugs, the long-acting drug delivery market is anticipated to witness substantial growth in the foreseen future.

Key Market Insights

The “Long-Acting Drug Delivery Technologies and Services Market, 2023-2035: Distribution by Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Compatible Dosage Form (Injectables, Implantables, Oral, Topical / Transdermal, Vaginal and Other Dosage Forms), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current technologies and service providers landscape and the likely future potential of the long-acting drug delivery technologies and services market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. The report answers the following key questions related to this domain.

What are the Benefits of Long-Acting Delivery of the Drugs?

The standard-of-care treatment options for several diseases, such as schizophrenia, Alzheimer’s disease, age-related macular degeneration, HIV prophylaxis, can be bothersome for patients because of regular intake of the prescribed medication. Patient non-compliance can further worsen the disease, where the medication is anticipated to be consumed for several months to years. In order to circumvent the high rate of non-compliance and non-adherence, long-acting drug delivery has been considered as a novel pharmacologic strategy. This delivery enables the continuous administration of active pharmaceutical ingredients (biologics, small molecules and peptides) for extended time period (weeks, months or years) after a single dose. The technological advancements in the field of long-acting drug delivery ascertain therapeutic efficacy, safety and improved drug pharmacokinetic and pharmacodynamic profiles. It is worth highlighting that, in 2021, the United States Food and Drug Administration (USFDA) approved Cabotegravir, the first long-acting injectable for the treatment of human immunodeficiency virus (HIV) pre-exposure prophylaxis, with the dosing regimen of once every two months. 

What is the Current Landscape of the Long-Acting Drug Delivery Technologies?

Currently, more than 100 long-acting drug delivery technologies are available / being developed by various industry stakeholders for the treatment of multiple diseases. The design of these technologies is based on either of the two principles, manipulation of drug release from delivery systems or manipulation of in vivo clearance. Amongst the strategies which allow the long-lasting effect, over 30% of the long-acting drug delivery technologies are suitable for long-acting implants / devices. It is worth mentioning that 70% of the technologies are compatible with injectables (depot and long-acting injections).

long-acting-drugs-market-landscape

What is the Need for Outsourcing Long-Acting Drug Development and Manufacturing Services to Contract Service Providers?

The development and manufacturing of these complex drug products requires great technical skill and scientific expertise. One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Also, scale-up and regulatory filing for a less-defined regulatory pathway often appear as a bottleneck in the clinical and commercial translation of these drugs. In order to mitigate these technical and operational complexities, pharmaceutical companies tend to outsource their operations to the players that offer services for the development and manufacturing of long-acting drugs.

What are the Key Trends in the Long-Acting Drug Delivery Technologies and Services Market?

Many stakeholders have been making consolidated efforts to forge alliance with other industry / non-industry players for technology licensing, product development and manufacturing purposes. It is worth highlighting that over 90 strategic partnerships have been inked since 2018 in this domain. Additionally, in the same time frame, more than 1,200 patents related to long-acting drug delivery have been filed / granted, highlighting the continuous pace of innovation in this field. Moreover, the field is evolving continuously, as researchers and industry players aim to enhance the existing technologies and delivery systems. In this context, in the past three years, over 360 long-acting drug delivery focused articles have been published. Given the inclination towards cutting-edge long-acting technologies, along with innovative approaches to tailor the dosing regimen, we believe that the long-acting drug delivery technologies and services market is likely to evolve at a rapid pace, over the coming years.

long-acting-drugs-market-trends

What is the Market Size of Long-Acting Drug Delivery Technologies and Services Market?

Lately, the pharmaceutical industry has witnessed the development of advanced long-acting drug delivery technology platforms. This is due to the ability of long-acting drugs to obviate the concerns associated with conventional treatment options. Eventually, these patient-centric treatment modalities aid in the reduction of treatment burden and need for surgical intervention. The global long-acting drug delivery technologies and services market is projected to grow at a CAGR of ~13% and ~11%, respectively, in the period 2023-2035. Further, in 2035, the long-acting drug delivery technologies market for micro-encapsulation is expected to capture the majority share. In terms of geography, the long-acting drug delivery services market in North America and Europe is anticipated to grow at a relatively faster pace by 2035.

long-acting-drugs-market-size

Who are the Key Players in the Long-Acting Drug Delivery Technologies and Services Market?

Examples of key players engaged in the long-acting drug delivery technology domain (which have also been captured in this report) include 3-D Matrix, Alnylam Pharmaceuticals, Amorphex Therapeutics, Bostal Drug Delivery, Cipla, Delpor, Heron Therapeutics and Nanexa. 
In addition, examples of key players offering long-acting drug delivery services (which have also been captured in this report) include Ascendia Pharmaceuticals, Caplin Steriles, Evonik, Indoco Remedies, Phosphorex and TTY Biopharm.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different attrributes / segments as defined in the below table:

Report Attribute Details

Forecast Period

2023 – 2035

Principal

Manipulation of drug release from delivery systems, Manipulation of in vivo clearance

Strategy

Chemical Modification, Micro-encapsulation, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions, Protein Fusion

Compatible Dosage Form

Injectables, Implantables, Oral, Topical / Transdermal, Vaginal, Other Dosage Forms

Type of Molecule Delivered

Small Molecules, Biologics, Other Molecules

Type of Material Used

Polymer based, Non-polymer based
Key Geographical Regions North America, Europe, Asia-Pacific, Middle East and North Africa
Key Companies Profiled Adare Pharma Solutions, AMW, Bostal Drug Delivery, Creative Biolabs, ForDoz Pharma, Innocore Pharmaceuticals, Integral BioSystems, LATITUDE Pharmaceuticals, Navin Saxena Research and Technology Centre (NSRT), Samyang Biopharm
Customization Scope 15% Free Customization Option (equivalent to 5 analyst working days)
PowerPoint Presentation (Complimentary) Available
Excel Data Packs (Complimentary) Technology Landscape Analysis, Service Providers Landscape Analysis, Technology Competitiveness Analysis, Company Competitiveness Analysis, Partnership and Collaboration Analysis, Publication Analysis, Patent Analysis, Grant Analysis, Market Forecast and Opportunity Analysis
  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of long-acting drug delivery technologies and services market and its likely evolution in the mid-long term.
  • A general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.
  • A detailed assessment of the current technology landscape of long-acting drug delivery technologies, based on several relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), type of material used (polymer based and non-polymer based), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), extended dosing interval(s) (weeks, months and years), type of molecule(s) delivered (biologics, small molecules and other molecules), highest phase of development (preclinical, clinical and approved), number of approved drugs and therapeutic area(s) (oncological disorders, ophthalmological disorders, neurological disorders, opioid use disorders / pain, women health, metabolic disorders, infectious diseases, cardiovascular disorders, autoimmune disorders, immunological disorders and others). In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, such as their year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).
  • A detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s) (contract development organization, contract manufacturing organization and contract development and manufacturing organization), scale of operation (preclinical, clinical and commercial), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), service(s) offered (product development, process development / pre-formulation, analytical method development, formulation development, manufacturing, technology transfer, stability studies, feasibility studies, scale-up, regulatory support and others) and type of molecule(s) supported (biologics, small molecules and other molecules).
  • A technology competitiveness analysis of long-acting drug delivery technologies based on developer power (in terms of the experience of the developer) and technology strength (in terms of principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development and therapeutic area(s)).
  • A company competitiveness analysis of long-acting drug delivery service providers based on company strength (in terms of years of experience and company size) and service strength (in terms of number of technology platform(s), type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported).
  • Elaborate profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery, located across North America, Europe and Asia-Pacific (shortlisted based on a proprietary criterion). Each profile features a brief overview of the company, details related to its technology portfolio, service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements. 
  • A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long-acting drug delivery, based on several relevant parameters, such as year of publication, type of publication and popular keywords. The chapter also highlights the top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).
  • An in-depth analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, type of grant application, purpose of grant award, activity code, NIH spending category, study section involved, popular NIH departments (in terms of number of grants) and type of recipient organization. Further, the chapter also highlights the prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants and amount awarded).

One of the key objectives of the report was to evaluate the current opportunity and future potential associated with long-acting drug delivery technologies and services market, over the coming 12 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), compatible dosage form (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), type of molecule delivered (small molecules, biologics and other molecules), type of material used (polymer based and non-polymer based) and key geographical regions (North America, Europe, Asia-Pacific and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with stakeholders in this domain. The report features detailed transcript of interview held with the industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are the major factors driving the long-acting drug delivery technologies and services market?
Answer: The need for improved patient convenience and compliance, medication adherence, lower dosage requirement for the treatment of several diseases, especially chronic diseases, has accentuated the demand for long-acting drug delivery formulations.

Question 2: How many long-acting drug delivery technologies, compatible with long-acting injectables, are available in the market?
Answer: Presently, more than 80 technologies available in the market are compatible with long-acting injectables.

Question 3: How many long-acting drug delivery technologies demonstrate extended dosage regimen of at least a year?
Answer: Close to 20 technologies support the development of long-acting injectables, long-acting implants and vaginal rings with superior dosing regimen of a year and above.

Question 4: What percent of the total contract service providers are offering both product development and manufacturing of long-acting drugs?
Answer: Close to 40% of the players involved in this domain claim to offer product development and manufacturing of long-acting drugs; notable examples include InnoCore Pharmaceuticals, Lubrizol Life Science Health, Mithra Pharmaceuticals, Pensatech Pharma.

Question 5: How many contract service providers possess technology transfer capabilities related to long-acting drug delivery?
Answer: Nearly 50% of the contract service providers engaged in this domain claim to have the requisite capabilities to aid in technology transfer of long-acting drug delivery technologies for the development of the long-acting drugs.

Question 6: What are the partnership and collaboration trends in the long-acting drug delivery domain?
Answer: Currently, product development agreements, technology licensing agreements and acquisitions are the most common types of partnerships inked by stakeholders in the long-acting drug delivery domain.

Question 7: What is the current patent landscape of long-acting drug delivery market?
Answer: 656 patents filed in this domain are patent applications, while 571 are granted patents. Of the total granted applications, close to 85% patents were filed in the US. 

Question 8: Which segment, in terms of strategies, accounts for the largest share in the global long-acting drug delivery technologies market?
Answer: Presently, micro-encapsulation strategy accounts for the largest share (close to 50%) of the global long-acting drug delivery technologies market. However, strategies, such as long-acting microneedles, multivesicular liposomes and long-acting hydrogels are likely to witness higher annual growth rates in the upcoming years. This can be attributed to the rising demand for such promising and versatile drug delivery-based technologies, characterized by distinct physical properties.

Question 9: Which geography is expected to witness the highest growth rate in the long-acting drug delivery services market?
Answer: The long-acting drug delivery services market in Europe is likely to grow at the highest CAGR, during the period 2023- 2035.

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long-Acting Drug Delivery
3.2.1. Types of Long-Acting Drug Delivery Systems

3.3. Long-Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies

3.4. Concluding Remarks

4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long-Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)

4.3. Long-Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long-Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported

6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long-Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long-Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long-Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long-Acting Drug Delivery Technologies offered by Very Large Companies

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long-Acting Drug Delivery Service Providers based in North America
7.4.2. Long-Acting Drug Delivery Service Providers based in Europe
7.4.3. Long-Acting Drug Delivery Service Providers based in Asia-Pacific

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook

8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook

8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook

8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook

8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook

8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook

8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long-Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long-Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long-Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization

11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics

11.5. Patent Valuation Analysis

12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long-Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long-Acting Drug Delivery Technologies Market, 2023-2035

13.3.1. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long-Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long-Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035

13.3.2. Long-Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long-Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long-Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035

13.3.3. Long-Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long-Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long-Acting Drug Delivery Technologies Market for Long-Acting Implants, 2023-2035
13.3.3.3. Long-Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long-Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long-Acting Drug Delivery Technologies Market for Long-Acting Hydrogels, 2023-2035
13.3.3.6. Long-Acting Drug Delivery Technologies Market for Long-Acting Microneedles, 2023-2035
13.3.3.7. Long-Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long-Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035

13.3.4. Long-Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long-Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long-Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long-Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long-Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long-Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long-Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035

13.3.5. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long-Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long-Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long-Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035

13.3.6. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long-Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long-Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035

13.3.7. Long-Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long-Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long-Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long-Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long-Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035

13.4. Global Long-Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long-Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long-Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long-Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long-Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long-Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long-Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long-Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035

13.4.2. Long-Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long-Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long-Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long-Acting Drug Delivery Services Market for Other Molecules, 2023-2035

13.4.3. Long-Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long-Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long-Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long-Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

14. CONCLUSION

15. INTERVIEW TRANSCRIPTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Technology Landscape
Figure 2.2 Executive Summary: Service Providers Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Grant Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis (Technology)
Figure 2.8 Executive Summary: Market Forecast and Opportunity Analysis (Service)
Figure 3.1 Types of Long-Acting Drug Delivery Systems
Figure 3.2 Principles and Strategies associated with Long-Acting Drug Delivery 
Figure 4.1 LADD Technologies: Distribution by Principle
Figure 4.2 LADD Technologies: Distribution by Strategy
Figure 4.3 LADD Technologies: Distribution by Type of Material Used
Figure 4.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Figure 4.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Figure 4.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Figure 4.7 LADD Technologies: Distribution by Highest Phase of Development
Figure 4.8 LADD Technologies: Distribution by Number of Approved Drugs
Figure 4.9 LADD Technologies: Distribution by Therapeutic Area(s)
Figure 4.10 LADD Technology Developers: Distribution by Year of Establishment
Figure 4.11 LADD Technology Developers: Distribution by Company Size
Figure 4.12 LADD Technology Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Technologies
Figure 5.1 LADD Contract Service Providers: Distribution by Year of Establishment
Figure 5.2 LADD Contract Service Providers: Distribution by Company Size
Figure 5.3 LADD Contract Service Providers: Distribution by Location of Headquarters
Figure 5.4 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 LADD Contract Service Providers: Distribution by Location of Facilities
Figure 5.6 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Figure 5.7 LADD Contract Service Providers: Distribution by Scale of Operation
Figure 5.8 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Figure 5.9 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Figure 5.10 LADD Contract Service Providers: Distribution by Service(s) Offered
Figure 5.11 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Figure 5.12 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Figure 5.13 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Figure 5.14 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Figure 6.1 Technology Competitiveness Analysis: LADD Technologies offered by Small Companies
Figure 6.2 Technology Competitiveness Analysis: LADD Technologies offered by Mid-sized Companies
Figure 6.3 Technology Competitiveness Analysis: LADD Technologies offered by Large Companies
Figure 6.4 Technology Competitiveness Analysis: LADD Technologies offered by Very Large Companies
Figure 7.1 Company Competitiveness Analysis: LADD Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: LADD Service Providers based in Europe
Figure 7.3 Company Competitiveness Analysis: LADD Service Providers based in Asia-Pacific
Figure 8.1 Adare Pharma Solutions: Service Portfolio
Figure 8.2 AMW: Service Portfolio
Figure 8.3 Bostal Drug Delivery: Service Portfolio
Figure 8.4 Creative Biolabs: Service Portfolio
Figure 8.5 ForDoz Pharma: Service Portfolio
Figure 8.6 InnoCore Pharmaceuticals: Service Portfolio
Figure 8.7 Integral BioSystems: Service Portfolio
Figure 8.8 LATITUDE Pharmaceuticals: Service Portfolio
Figure 8.9 Navin Saxena Research and Technology Centre (NSRT): Service Portfolio
Figure 8.10 Samyang Biopharm: Service Portfolio
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Regional Distribution
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.10 Partnerships and Collaborations: Local and International Deals
Figure 10.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Most Popular Journals: Distribution by Number of Publications
Figure 10.4 Most Popular Publishers: Distribution by Number of Publications
Figure 10.5 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.6 Most Popular Keywords: Distribution by Number of Publications
Figure 10.7 Key Funding Institutes: Distribution by Number of Publications
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Figure 11.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 11.4 Patent Analysis: Distribution by Geography
Figure 11.5 Patent Analysis: Distribution by CPC Symbols
Figure 11.6 Leading Industry Players: Distribution by Number of Patents
Figure 11.7 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 11.8 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 11.9 Patent Analysis: Distribution by Patent Age (2018-2022)
Figure 11.10 Patent Analysis: Patent Valuation
Figure 12.1 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Figure 12.2 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Figure 12.3 Grant Analysis: Distribution by Support Period
Figure 12.4 Grant Analysis: Distribution by Support Period and Funding Institute Center
Figure 12.5 Grant Analysis: Distribution by Type of Grant Application
Figure 12.6 Grant Analysis: Distribution by Purpose of Grant Award
Figure 12.7 Grant Analysis: Distribution by Activity Code
Figure 12.8 Word Cloud: NIH Spending Category
Figure 12.9 Grant Analysis: Distribution by Study Section Involved
Figure 12.10 Popular NIH Departments: Distribution by Number of Grants
Figure 12.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.12 Prominent Program Officers: Distribution by Number of Grants
Figure 12.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.14 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Figure 12.15 Grant Analysis: Distribution by Region of Recipient Organization
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global Long-Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Figure 13.4 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Figure 13.5 Long-Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Figure 13.6 Long-Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Figure 13.7 Long-Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Figure 13.8 Long-Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Figure 13.9 Long-Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Figure 13.10 Long-Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Figure 13.11 Long-Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Figure 13.12 Long-Acting Drug Delivery Technologies Market for Long-Acting Implants, 2023-2035 (USD Billion)
Figure 13.13 Long-Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Figure 13.14 Long-Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Figure 13.15 Long-Acting Drug Delivery Technologies Market for Long-Acting Hydrogels, 2023-2035 (USD Billion)
Figure 13.16 Long-Acting Drug Delivery Technologies Market for Long-Acting Microneedles, 2023-2035 (USD Billion)
Figure 13.17 Long-Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Figure 13.18 Long-Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Figure 13.19 Long-Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.20 Long-Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Figure 13.21 Long-Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Figure 13.22 Long-Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.23 Long-Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.24 Long-Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Figure 13.25 Long-Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Figure 13.26 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Figure 13.27 Long-Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Figure 13.28 Long-Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Figure 13.29 Long-Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Figure 13.30 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Figure 13.31 Long-Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Figure 13.32 Long-Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Figure 13.33 Long-Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.34 Long-Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Figure 13.35 Long-Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Figure 13.36 Long-Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.37 Long-Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Figure 13.38 Global Long-Acting Drug Delivery Services Market, 2023-2035
Figure 13.39 Long-Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.40 Long-Acting Drug Delivery Services Market for Injectables, 2023-2035
Figure 13.41 Long-Acting Drug Delivery Services Market for Implantables, 2023-2035
Figure 13.42 Long-Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Figure 13.43 Long-Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Figure 13.44 Long-Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Figure 13.45 Long-Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Figure 13.46 Long-Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Figure 13.47 Long-Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Figure 13.48 Long-Acting Drug Delivery Services Market for Biologics, 2023-2035
Figure 13.49 Long-Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Figure 13.50 Long-Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.51 Long-Acting Drug Delivery Services Market in North America, 2023-2035
Figure 13.52 Long-Acting Drug Delivery Services Market in Europe, 2023-2035
Figure 13.53 Long-Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
Figure 14.1 Concluding Remarks: Overall Technology Landscape
Figure 14.2 Concluding Remarks: Overall Service Providers Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Grant Analysis
Figure 14.7 Concluding Remarks: Market Forecast and Opportunity Analysis (Technology)
Figure 14.8 Concluding Remarks: Market Forecast and Opportunity Analysis (Service)

List Of Tables

Table 4.1 LADD Technologies: Information on Principle
Table 4.2 LADD Technologies: Information on Strategy
Table 4.3 LADD Technologies: Information on Type of Material Used
Table 4.4 LADD Technologies: Information on Compatible Dosage Form(s)
Table 4.5 LADD Technologies: Information on Extended Dosing Interval(s)
Table 4.6 LADD Technologies: Information on Type of Molecule(s) Delivered
Table 4.7 LADD Technologies: Information on Highest Phase of Development
Table 4.8 LADD Technologies: Information on Approved Drugs
Table 4.9 LADD Technologies: Information on Therapeutic Area(s)
Table 4.10 LADD Technologies: List of Technology Developers
Table 5.1 LADD Contract Service Providers: List of Service Providers
Table 5.2 LADD Contract Service Providers: Information on Scale of Operation
Table 5.3 LADD Contract Service Providers: Information on Compatible Dosage Form(s)
Table 5.4 LADD Contract Service Providers: Information on Service(s) Offered
Table 5.5 LADD Contract Service Providers: Information on Type of Molecule(s) Supported
Table 8.1 List of Companies Profiled
Table 8.2 Adare Pharma Solutions: Company Overview
Table 8.3 Adare Pharma Solutions: Technology Portfolio
Table 8.4 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 8.5 AMW: Company Overview
Table 8.6 AMW: Technology Portfolio
Table 8.7 AMW: Recent Developments and Future Outlook
Table 8.8 Bostal Drug Delivery: Company Overview
Table 8.9 Bostal Drug Delivery: Technology Portfolio
Table 8.10 Creative Biolabs: Company Overview
Table 8.11 Creative Biolabs: Technology Portfolio
Table 8.12 Creative Biolabs: Recent Developments and Future Outlook
Table 8.13 ForDoz Pharma: Company Overview
Table 8.14 ForDoz Pharma: Technology Portfolio
Table 8.15 ForDoz Pharma: Recent Developments and Future Outlook
Table 8.16 InnoCore Pharmaceuticals: Company Overview
Table 8.17 InnoCore Pharmaceuticals: Technology Portfolio
Table 8.18 InnoCore Pharmaceuticals: Recent Developments and Future Outlook
Table 8.19 Integral BioSystems: Company Overview
Table 8.20 Integral BioSystems: Technology Portfolio
Table 8.21 Integral BioSystems: Recent Developments and Future Outlook
Table 8.22 LATITUDE Pharmaceuticals: Company Overview
Table 8.23 LATITUDE Pharmaceuticals: Technology Portfolio
Table 8.24 Navin Saxena Research and Technology Centre (NSRT): Company Overview
Table 8.25 Navin Saxena Research and Technology Centre (NSRT): Technology Portfolio
Table 8.26 Samyang Biopharm: Company Overview
Table 8.27 Samyang Biopharm: Technology Portfolio
Table 8.28 Samyang Biopharm: Recent Developments and Future Outlook
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Partner, 2018-2022
Table 9.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise), 2018-2022
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Codes
Table 11.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 11.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 13.1 Long-Acting Drug Delivery Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2022 (USD Million)
Table 16.1 LADD Technologies: Distribution by Principle
Table 16.2 LADD Technologies: Distribution by Strategy
Table 16.3 LADD Technologies: Distribution by Type of Material Used
Table 16.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Table 16.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Table 16.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Table 16.7 LADD Technologies: Distribution by Highest Phase of Development
Table 16.8 LADD Technologies: Distribution by Number of Approved Drugs
Table 16.9 LADD Technologies: Distribution by Therapeutic Area(s)
Table 16.10 LADD Technology Developers: Distribution by Year of Establishment
Table 16.11 LADD Technology Developers: Distribution by Company Size
Table 16.12 LADD Technology Developers: Distribution by Location of Headquarters
Table 16.13 Most Active Players: Distribution by Number of Technologies
Table 16.14 LADD Contract Service Providers: Distribution by Year of Establishment
Table 16.15 LADD Contract Service Providers: Distribution by Company Size
Table 16.16 LADD Contract Service Providers: Distribution by Location of Headquarters
Table 16.17 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.18 LADD Contract Service Providers: Distribution by Location of Facilities
Table 16.19 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Table 16.20 LADD Contract Service Providers: Distribution by Scale of Operation
Table 16.21 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Table 16.22 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Table 16.23 LADD Contract Service Providers: Distribution by Service(s) Offered
Table 16.24 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Table 16.25 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Table 16.26 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Table 16.27 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Table 16.28 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.32 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 16.33 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 16.34 Most Active Players: Distribution by Number of Partnerships
Table 16.35 Partnerships and Collaborations: Regional Distribution
Table 16.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 16.37 Partnerships and Collaborations: Local and International Deals
Table 16.38 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 16.39 Publication Analysis: Distribution by Type of Publication
Table 16.40 Most Popular Journals: Distribution by Number of Publications
Table 16.41 Most Popular Publishers: Distribution by Number of Publications
Table 16.42 Most Popular Copyright Holders: Distribution by Number of Publications
Table 16.43 Key Funding Institutes: Distribution by Number of Publications
Table 16.44 Patent Analysis: Distribution by Type of Patent
Table 16.45 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Table 16.46 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.47 Patent Analysis: Distribution by Geography
Table 16.48 Patent Analysis: Distribution by CPC Symbols
Table 16.49 Leading Industry Players: Distribution by Number of Patents
Table 16.50 Patent Analysis: Cumulative Distribution by Type of Organization
Table 16.51 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 16.52 Patent Analysis: Distribution by Patent Age (2018-2022)
Table 16.53 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Table 16.54 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Table 16.55 Grant Analysis: Distribution by Support Period
Table 16.56 Grant Analysis: Distribution by Support Period and Funding Institute Center
Table 16.57 Grant Analysis: Distribution by Type of Grant Application
Table 16.58 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.59 Grant Analysis: Distribution by Activity Code
Table 16.60 Grant Analysis: Distribution by Study Section Involved
Table 16.61 Popular NIH Departments: Distribution by Number of Grants
Table 16.62 Grant Analysis: Distribution by Type of Recipient Organization
Table 16.63 Prominent Program Officers: Distribution by Number of Grants
Table 16.64 Popular Recipient Organizations: Distribution by Number of Grants
Table 16.65 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Table 16.66 Grant Analysis: Distribution by Region of Recipient Organization
Table 16.67 Global Long-Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Table 16.68 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Table 16.69 Long-Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Table 16.70 Long-Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Table 16.71 Long-Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Table 16.72 Long-Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Table 16.73 Long-Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Table 16.74 Long-Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Table 16.75 Long-Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Table 16.76 Long-Acting Drug Delivery Technologies Market for Long-Acting Implants, 2023-2035 (USD Billion)
Table 16.77 Long-Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Table 16.78 Long-Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Table 16.79 Long-Acting Drug Delivery Technologies Market for Long-Acting Hydrogels, 2023-2035 (USD Billion)
Table 16.80 Long-Acting Drug Delivery Technologies Market for Long-Acting Microneedles, 2023-2035 (USD Billion)
Table 16.81 Long-Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Table 16.82 Long-Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Table 16.83 Long-Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.84 Long-Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Table 16.85 Long-Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Table 16.86 Long-Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Table 16.87 Long-Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Table 16.88 Long-Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Table 16.89 Long-Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Table 16.90 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Table 16.91 Long-Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Table 16.92 Long-Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Table 16.93 Long-Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Table 16.94 Long-Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Table 16.95 Long-Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Table 16.96 Long-Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Table 16.97 Long-Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Table 16.98 Long-Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Table 16.99 Long-Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Table 16.100 Long-Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 16.101 Long-Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Table 16.102 Global Long-Acting Drug Delivery Services Market, 2023-2035
Table 16.103 Long-Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.104 Long-Acting Drug Delivery Services Market for Injectables, 2023-2035
Table 16.105 Long-Acting Drug Delivery Services Market for Implantables, 2023-2035
Table 16.106 Long-Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Table 16.107 Long-Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Table 16.108 Long-Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Table 16.109 Long-Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Table 16.110 Long-Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Table 16.111 Long-Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Table 16.112 Long-Acting Drug Delivery Services Market for Biologics, 2023-2035
Table 16.113 Long-Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Table 16.114 Long-Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Table 16.115 Long-Acting Drug Delivery Services Market in North America, 2023-2035
Table 16.116 Long-Acting Drug Delivery Services Market in Europe, 2023-2035
Table 16.117 Long-Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3-D Matrix
  2. Accord BioPharma
  3. Accord Healthcare
  4. Adare Pharma Solutions
  5. Adello Biologics (Subsidiary of Kashiv BioSciences)
  6. ADVANZ PHARMA
  7. Aequus Pharmaceuticals
  8. AffaMed Therapeutics
  9. ALAR Pharmaceuticals
  10. Alkermes
  11. Allergan
  12. Alnylam Pharmaceuticals
  13. ALTEOGEN
  14. Amorphex Therapeutics
  15. AMW
  16. Antares Pharma
  17. Anticancer Bioscience
  18. Aptys pharma
  19. argenx
  20. Ascendia Pharmaceuticals
  21. Ascendis Pharma
  22. AstraZeneca
  23. Auritec Pharmaceuticals
  24. Avomeen
  25. Bayer
  26. Biogen
  27. Bostal Drug Delivery
  28. Cali Biosciences
  29. Camurus
  30. Caplin Steriles
  31. Catalent
  32. CD Formulation
  33. Celanese
  34. Changchun GenScience Pharmaceuticals
  35. Chugai Pharmaceutical
  36. Cidara Therapeutics
  37. Cipla
  38. CMC Pharmaceuticals
  39. Corium
  40. Creative Biolabs
  41. CS Pharmaceuticals
  42. Daiichi Sankyo
  43. Dare Bioscience
  44. Delpor
  45. DelSiTech
  46. Dr. Reddy's Laboratories
  47. Drug Delivery Experts (Subsidiary of Pace Life Sciences)
  48. DSM Biomedical
  49. DURECT
  50. Dutch Research Council (NWO)
  51. Endo International
  52. Equinox
  53. Eupraxia Pharmaceuticals
  54. Eurofarma
  55. Evonik
  56. Eximore
  57. Extend Biosciences
  58. EyePoint Pharmaceuticals
  59. ForDoz Pharma
  60. Foresee Pharmaceuticals
  61. Foster Delivery Science
  62. Frazier Healthcare Partners
  63. Freudenberg Medical
  64. G2GBIO
  65. Genovior Biotech
  66. Gilead Sciences
  67. Gland Pharma
  68. GP Pharm
  69. Graybug Vision
  70. Gurnet Point Capital
  71. Halozyme
  72. Hanmi Pharmaceutical
  73. Heron Therapeutics
  74. Horizon Therapeutics
  75. Humanwell Pharmaceutical US
  76. Humedix
  77. Hyalo Technologies
  78. Hybio Pharmaceutical
  79. ImmunoForge
  80. ImprimisRx
  81. Indegene
  82. Indoco Remedies
  83. Inflammasome Therapeutics
  84. Innocan Pharma
  85. InnoCore Pharmaceuticals
  86. Innovare Labs
  87. Intarcia Therapeutics
  88. Intas Pharmaceuticals
  89. Integral BioSystems
  90. INTRAGEL
  91. IVERIC bio
  92. iVIEW Therapeutics
  93. Janssen Pharmaceuticals
  94. Jazz Pharmaceuticals
  95. JT Pharmaceuticals
  96. Juniper Pharmaceuticals
  97. Kashiv BioSciences
  98. Korea Pharma
  99. LATITUDE Pharmaceuticals
  100. LayerBio
  101. LipoCure
  102. LipoMedix
  103. Lubrizol Life Science Health
  104. Lucideon
  105. Lupin
  106. Luye Pharma
  107. Lyndra Therapeutics
  108. Lynkogen
  109. Mati Therapeutics
  110. Medical University of South Carolina (MUSC) Foundation
  111. Medicines Patent Pool
  112. MedinCell
  113. Megapharm
  114. Melinta Therapeutics
  115. Merck
  116. Micropore Technologies
  117. Midatech Pharma
  118. Mireca Medicines
  119. Mistral Capital Management
  120. Mithra Pharmaceuticals
  121. Molteni Farmaceutici
  122. Mucommune
  123. Mundipharma
  124. Nacuity Pharmaceuticals
  125. Nanexa
  126. Nano Precision Medical
  127. Nanoform
  128. NanOlogy
  129. NanoMedical Systems
  130. Nanomi
  131. National Institute of Allergy and Infectious Diseases
  132. Navin Saxena Research and Technology Centre (NSRT)
  133. NBCD
  134. Oakwood Laboratories
  135. Ocular Therapeutix
  136. Oculinea
  137. Ocumension Therapeutics
  138. OncoLize
  139. OPKO Biologics
  140. Ovensa
  141. Pace Life Sciences
  142. Pacira Pharmaceuticals
  143. Pensatech Pharma
  144. Peptron
  145. PharmaMar
  146. Pharmathen
  147. PharmSky Research
  148. PhaseBio Pharmaceuticals
  149. Phosphorex
  150. Picosun
  151. PolyActiva
  152. PolyPid
  153. Population Council
  154. ProJect Pharmaceutics
  155. ProLynx
  156. ProMed Pharma
  157. pSivida
  158. Ra Pharmaceuticals
  159. Ramot
  160. ReBio Technologies
  161. Recipharm
  162. Re-Vana Therapeutics
  163. Ripple Therapeutics
  164. Roche
  165. Rodin Therapeutics (Subsidiary of Alkermes)
  166. Samsung Biologics
  167. Samyang Biopharm
  168. Samyang Holdings
  169. SanaVita Medical
  170. Secant
  171. SENTAN Pharma
  172. Serina Therapeutics
  173. Sevaredent Sourcing Solutions
  174. Sever Pharma Solutions
  175. SHILPA Therapeutics
  176. Societal CDMO
  177. Sonoran Biosciences
  178. SpineThera
  179. Spinnaker Biosciences
  180. Starpharma
  181. SurModics
  182. Synartro
  183. Tandem Nano
  184. Teikoku Pharma USA
  185. Théa Open Innovation
  186. Thomas H. Lee Partners
  187. Tianjin Chase Sun Pharmaceutical
  188. Titan Pharmaceuticals
  189. TLC
  190. Tolmar Pharmaceuticals
  191. TOWA PHARMACEUTICAL
  192. TREKKA Therapeutics
  193. Trelleborg Sealing Solutions
  194. TTY Biopharm
  195. Vantage Surgical Solutions
  196. ViiV Healthcare
  197. Virpax Pharmaceuticals
  198. Visus Therapeutics
  199. Vitranu
  200. VIVA Biotech
  201. Xenetic Biosciences
  202. Yissum Research and Development
  203. Yunfeng Capital
  204. Zhejiang Langhua Pharmaceutical

Source 1: https://pubmed.ncbi.nlm.nih.gov/35363574/
Source 2: https://www.nih.gov/news-events/news-releases/nih-celebrates-fda-approval-long-acting-injectable-drug-hiv-prevention

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com